NICE guidance - beta interferon for the treatment of multiple sclerosis

Last edited 07/2018

• Glatiramer acetate is recommended as an option for treating multiple sclerosis, only if:
  • the person has relapsing-remitting multiple sclerosis and
  • the company provides it according to the commercial arrangement
    
    
• Interferon beta-1a is recommended as an option for treating multiple sclerosis, only if:
  • the person has relapsing-remitting multiple sclerosis and
  • the companies provide it according to commercial arrangement
    
    
• Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:
  • the person has relapsing-remitting multiple sclerosis and has had 2or more relapses within the last 2 years or
  • the person has secondary progressive multiple sclerosis with continuing relapses
  • and the company provides it according to the commercial arrangement.

Reference:

(1) NICE (June 2018). Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. Web: www.nice.org.uk